BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10410145)

  • 1. [Internal radiation therapy for malignant neoplasm].
    Yokoyama K; Kinuya S; Tonami N
    Gan To Kagaku Ryoho; 1999 May; 26(6):768-74. PubMed ID: 10410145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent progress in radionuclide therapy].
    Kasagi K; Iwata M; Misaki T; Konishi J; Sakahara H
    Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Nov; 60(13):729-37. PubMed ID: 11140321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nuclear medicine therapy of bone metastases].
    Kimmig B; Hermann HJ; Kober B
    Rontgenblatter; 1983 Jul; 36(7):216-9. PubMed ID: 6622951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
    Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
    Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palliative radiation therapy of symptomatic recurrent bladder cancer.
    Yi SK; Yoder M; Zaner K; Hirsch AE
    Pain Physician; 2007 Mar; 10(2):285-90. PubMed ID: 17387350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).
    Kan MK
    Cancer Nurs; 1995 Aug; 18(4):286-91. PubMed ID: 7545083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effectiveness of iodine-131 MIBG metastases of a nonsecreting paraganglioma.
    Baulieu JL; Guilloteau D; Baulieu F; Le Floch O; Chambon C; Pourcelot L; Besnard JC
    J Nucl Med; 1988 Dec; 29(12):2008-13. PubMed ID: 3193214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of radioisotopes for palliation of metastatic bone pain.
    Gkialas I; Iordanidou L; Galanakis I; Giannopoulos S
    J BUON; 2008; 13(2):177-83. PubMed ID: 18555462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear medicine therapy of neuroblastoma.
    Hoefnagel CA
    Q J Nucl Med; 1999 Dec; 43(4):336-43. PubMed ID: 10731784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
    Giammarile F; Mognetti T; Resche I
    Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
    Weber W; Weber J; Senekowitsch-Schmidtke R
    Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.
    Pandit-Taskar N; Batraki M; Divgi CR
    J Nucl Med; 2004 Aug; 45(8):1358-65. PubMed ID: 15299062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
    Lind P; Igerc I; Kohlfürst S
    Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
    Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
    J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.